Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Oncology and palliative care indexChapter sections
Purpose and principlesIndications, selection and cautionsAssessment before treatmentTreatment approachRegimens, contraindications and interactionsComplications, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook10 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

CAR-T and cellular therapy

Oncology and palliative care · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

Fever, hypotension or hypoxia after cellular therapy may be cytokine-release syndrome but infection must be treated in parallel. Confusion, language disturbance, tremor, weakness, seizure or reduced consciousness may represent immune-effector-cell neurotoxicity. Contact the CAR-T centre immediately, use protocol grading and escalate early to critical care; do not give empiric corticosteroid without specialist direction unless immediate resuscitation requires it.

Purpose and principles

Explain referral, manufacture and delivery of CAR-T and other cellular therapies, coordinate bridging and lymphodepletion, and recognise cytokine-release, neurotoxic, infective and prolonged haematological complications.

CAR-T manufacture begins with leukapheresis, followed by ex vivo gene transfer, expansion, quality testing and return of the product. The patient may need bridging therapy while waiting. Shortly before infusion, lymphodepleting chemotherapy creates an immune environment that supports CAR-T expansion. Product identity, chain of custody and fitness for infusion are critical because each autologous product belongs to one patient.

CAR-T activation produces cytokines and endothelial effects. Cytokine-release syndrome ranges from fever to vasodilatory shock and respiratory failure. Neurotoxicity may present subtly with handwriting or naming difficulty before seizures or cerebral oedema. Infection, tumour progression, metabolic disturbance and medicine effects remain competing or coexisting diagnoses. Specialist grading determines tocilizumab, corticosteroid, antiseizure and critical-care escalation.

Indications, selection and cautions

Cytokine-release syndrome

Fever followed by hypotension or hypoxia after infusion requires grading, sepsis treatment and specialist cytokine-directed therapy.

Early neurotoxicity

Inattention, handwriting change, word-finding difficulty, tremor or altered behaviour may precede severe encephalopathy.

Severe ICANSRed flag

Seizure, motor deficit, reduced consciousness or features of cerebral oedema require immediate neurocritical and CAR-T-centre management.

Prolonged immune deficiency

Persistent cytopenia, recurrent infection and low immunoglobulin can continue after hospital discharge and need specialist prevention.

Manufacturing or bridging failure

Progressive disease, infection or organ decline between collection and infusion can alter eligibility and require rapid MDT reconsideration.

Assessment before treatment

  1. 01
    Eligibility and disease assessmentFirst step
    Why
    Confirm commissioned indication, response need and physiological fitness before collection.
    Interpretation and limitations
    Review histology, antigen context, prior therapy, organ function, infection and realistic bridging options with the CAR-T centre.
  2. 02
    Pre-infusion infection and organ screen
    Why
    Identify contraindications and establish a baseline before lymphodepletion.
    Interpretation and limitations
    Include protocol virology, blood count, renal, hepatic, cardiac and neurological assessment; active infection may require delay.
  3. 03
    CRS monitoring panel
    Why
    Assess fever physiology and organ dysfunction after infusion.
    Interpretation and limitations
    Vital signs, cultures, blood count, renal, hepatic, coagulation and inflammatory trends support grading but no single marker distinguishes CRS from sepsis.
  4. 04
    Structured neurological score
    Why
    Detect early ICANS and follow change over time.
    Interpretation and limitations
    Use the centre's repeated cognitive, language, writing and consciousness assessment; imaging, EEG and lumbar tests are added for severity and differentials.
  5. 05
    Late immune and disease assessment

Treatment approach

01ReferPrepare and collect cellsFirst stepA patient may meet a commissioned CAR-T indication.+
  1. 1Refer early to the designated centre with pathology, treatment history, disease burden, performance and organ data.
  2. 2Confirm consent, caregiver and travel arrangements, infection screening and leukapheresis suitability while planning a realistic bridging strategy.
  3. 3Preserve chain of identity through collection and manufacture and create a contingency if product or disease control fails.
02InfuseLymphodeplete and deliver productManufacture succeeds and the patient remains eligible.+
  1. 1Reassess disease, infection, organ function and medicines before protocol lymphodepletion and product release.
  2. 2Verify unique identity and administer through the accredited cellular-therapy process with rescue medicines and critical-care access available.

Regimens, contraindications and interactions

Blocks interleukin-6 receptor signalling in clinically significant cytokine-release syndrome while sepsis assessment and organ support continue.

Tocilizumab for CAR-T cytokine-release syndrome

For adults weighing at least 30 kg, give 8 mg/kg intravenously over 60 minutes, maximum 800 mg per dose. If there is no clinical improvement, up to 3 additional doses may be given at intervals of at least 8 hours, within the CAR-T centre protocol.

Do not let cytokine-directed treatment delay cultures, antimicrobials or shock care. Monitor liver, blood count and infection; isolated ICANS may not respond, and significant neurotoxicity requires its own protocol-directed treatment.

Complications, monitoring and follow-up

  • Record temperature, blood pressure, oxygen requirement and organ function at the centre-defined frequency after infusion.
  • Perform repeated structured neurological and handwriting assessment, escalating subtle trajectory changes before consciousness falls.
  • Trend blood count, coagulation, renal, hepatic and inflammatory markers while treating infection and tumour lysis in parallel.
  • After discharge monitor cytopenia, immunoglobulin, infection, vaccination status, neurological function and disease response.
  • Maintain long-term registry, product traceability and alert-card information for delayed toxicity and secondary malignancy surveillance.

Special situations

CRS and sepsis coexist

Fever timing can suggest cytokine release, but immunocompromised patients still need cultures and empirical infection treatment.

Writing is sensitive

A change in a simple sentence can reveal early language and attention dysfunction before gross disorientation appears.

Tocilizumab is not universal

It treats CRS biology but may not control isolated neurotoxicity, which follows a different specialist algorithm.

Manufacture is clinical time

The weeks between collection and product release need active disease, infection and organ planning, not passive waiting.

Late care is substantial

Successful acute discharge does not end risk from cytopenia, hypogammaglobulinaemia, infection and delayed relapse.

Common pitfalls

  1. 01

    Calling all post-infusion fever CRS.

  2. 02

    Waiting for severe confusion before neurological scoring.

  3. 03

    Giving tocilizumab as sole treatment for isolated ICANS.

  4. 04

    Ignoring disease progression during manufacture.

  5. 05

    Losing chain of identity documentation.

  6. 06

    Ending follow-up after acute discharge.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Oncology and palliative careOriginal SBA

Fever after CAR-T

A patient develops fever and hypotension three days after CAR-T infusion. Which immediate principle is safest within the current specialist cancer pathway?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Oncology and palliative care topics →
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NHS England CAR-T therapy service specificationCommissioned-centre requirements, pathway governance, traceability and management of CAR-T toxicities.
  • NHS England adult cancer chemotherapy service specificationCurrent requirements for safe, protocol-governed systemic anticancer treatment services.
  • NHS England cancer programmeAcute oncology, critical-care integration and national access to specialised treatment.
  • NICE shared decision making recommendationsConsent for manufacturing uncertainty, serious toxicity and alternative care.
  • Tocilizumab Summary of Product CharacteristicsWeight-based CAR-T CRS dose, 800 mg maximum and repeat-dose interval and limit.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
Late care includes antimicrobial prophylaxis, vaccination planning, immunoglobulin assessment, cytopenia surveillance and disease response. B-cell aplasia can indicate on-target activity but increases infection risk. Patients should avoid driving and remain near the treating centre for the specified period. Long-term registries and follow-up capture delayed neurological, infectious, haematological and second-cancer outcomes.

Key points

  • CAR-T therapy uses genetically modified autologous T cells to recognise a tumour surface antigen and is delivered only through commissioned specialist centres.
  • The pathway includes eligibility, cell collection, manufacture, bridging treatment where needed, lymphodepletion, infusion and prolonged toxicity surveillance.
  • Manufacturing time and failure are clinically important; disease can progress before infusion and bridging therapy must not compromise organ reserve or cell delivery.
  • Cytokine-release syndrome causes fever, hypotension and hypoxia, usually early, but sepsis has overlapping physiology and requires cultures and empirical antimicrobials.
  • Immune-effector-cell-associated neurotoxicity can cause inattention, dysgraphia, aphasia, tremor, seizure or cerebral oedema and may occur with or after cytokine-release syndrome.
  • Tocilizumab is used for protocol-defined significant cytokine-release syndrome. For significant ICANS, contact the CAR-T centre and start centre-protocol corticosteroid without delay when indicated; fever alone is not a reason for unstructured empirical steroid dosing.
  • Prolonged cytopenia, hypogammaglobulinaemia, opportunistic infection, tumour lysis and secondary malignancy require months to years of follow-up.
  • Patients and carers need accommodation, transport, emergency contact and a written alert because safe treatment depends on rapid return to the specialist centre.
Why
Monitor cytopenia, immunoglobulin, infection and cancer response.
Interpretation and limitations
Interpret B-cell aplasia and marrow recovery with product and disease context; prolonged abnormalities require specialist follow-up.
  • 3Begin scheduled vital-sign and neurological monitoring and ensure all teams know the product, infusion date and emergency centre contact.
    • 03RescueTreat fever or neurological changeSymptoms compatible with CRS, infection or ICANS develop.+
    1. 1Use ABCDE assessment, obtain cultures and give empirical antimicrobials for possible infection while grading CRS and neurological toxicity.
    2. 2For significant CRS give tocilizumab according to centre protocol; for significant ICANS contact the CAR-T centre and start protocol corticosteroid without delay when indicated, adding antiseizure and organ support and involving critical care before refractory shock or cerebral oedema.
    3. 3Continue frequent reassessment after initial improvement because CRS and neurotoxicity can evolve on different timelines.